Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.46 |
| ▸ | GAK | O14976 | 3/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114268 | 1.00 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL3931282 | 1.00 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL4114369 | 0.83 | PDE4A (0.65) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL3930176 | 0.82 | GAK (0.63) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL4118609 | 0.82 | PDE4A (0.61) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL3922080 | 0.80 | PDE4A (0.55) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL4121554 | 0.80 | PDE4A (0.55) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL3921361 | 0.80 | PDE4A (0.55) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL4113536 | 0.80 | PDE4D (0.73) | PDE4DPDE4APDE4BPDE4CNOS1 | |
| SCHEMBL3920481 | 0.80 | PDE4A (0.59) | PDE4DPDE4APDE4BPDE4CNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | claimed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | claimed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899332-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| EP-1831217-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006069805-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069805-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | PDE4D 1645/4885PDE4A 1370/4885PDE4B 1438/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | PDE4D 197/4885PDE4A 112/4885PDE4B 313/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | PDE4D 197/4885PDE4A 112/4885PDE4B 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.